J-Pharma Co., Ltd. (520A)
Market Closed
2 Oct, 06:08 AM
JPX JPX Primary ¥
399. 00
-16
-3.8554%
¥
8.02B Market Cap
- P/E Ratio
- Div Yield
55,900 Volume
- Eps
¥ 415
Previous Close Want to track 520A and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Summary
520A closed Friday lower at ¥399, a decrease of -3.8554% from Thursday's close, completing a monthly decrease of -1.9656% or -¥8. Over the past 12 months, 520A stock lost -50.6799%.
520A is not paying dividends to its shareholders.
The stock of the company had never split.
The company's stock is traded on one exchange.
520A Chart
J-Pharma Co., Ltd. (520A) FAQ
What is the stock price today?
The current price is ¥399.00.
On which exchange is it traded?
J-Pharma Co., Ltd. is listed on JPX.
What is its stock symbol?
The ticker symbol is 520A.
Does it pay dividends? What is the current yield?
It does not pay dividends to its shareholders.
What is its market cap?
As of today, the market cap is 8.02B.
Has J-Pharma Co., Ltd. ever had a stock split?
No, there has never been a stock split.
J-Pharma Co., Ltd. Profile
| - Industry | - Sector | Mr. Masuhiro Yoshitake CEO | JPX Exchange | - ISIN |
| Japan Country | - Employees | - Last Dividend | - Last Split | - IPO Date |
J-Pharma Co., Ltd. is a biopharmaceutical company specializing in the development of innovative drugs targeting SLC transporters, which are membrane proteins that transport substances across cell membranes. The company focuses primarily on LAT1, an essential amino acid transporter overexpressed in cancer cells and correlated with malignancy and poor prognosis. Its lead compound, nanvuranlat, is an LAT1 inhibitor advancing in clinical development for biliary tract cancer, demonstrating improved progression-free survival in patients resistant to standard chemotherapy. J-Pharma Co., Ltd. is also exploring LAT1 inhibitors for pancreatic cancer, colorectal cancer, kidney cancer, brain cancer, and autoimmune diseases. Through proprietary technologies originating from academic research, the company pursues novel therapies to address unmet medical needs in oncology and beyond. Founded in 2005 and headquartered in Tokyo, Japan, J-Pharma Co., Ltd. engages in drug discovery and development to provide new treatment options for refractory diseases.
Contact Information
Address: 8th Floor, VORT Hamamatsucho II
Phone: 81 3 6432 4270
Website: https://www.j-pharma.com
2026 © Marketlog. All Rights Reserved.
